
Noble E. Jarrell
Examiner (ID: 14167, Phone: (571)272-9077 , Office: P/1625 )
| Most Active Art Unit | 1699 |
| Art Unit(s) | 1625, 1699, 1622, 1624, 1609 |
| Total Applications | 1419 |
| Issued Applications | 950 |
| Pending Applications | 180 |
| Abandoned Applications | 334 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 13717017
[patent_doc_number] => 20170369463
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-12-28
[patent_title] => ESTERIFICATION OF 2,5-FURAN-DICARBOXYLIC ACID
[patent_app_type] => utility
[patent_app_number] => 15/674726
[patent_app_country] => US
[patent_app_date] => 2017-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5646
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15674726
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/674726 | Esterification of 2,5-furan-dicarboxylic acid | Aug 10, 2017 | Issued |
Array
(
[id] => 12979654
[patent_doc_number] => 20170342089
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-11-30
[patent_title] => NOVEL COMPOUNDS AS MODULATORS OF GPR-119
[patent_app_type] => utility
[patent_app_number] => 15/674376
[patent_app_country] => US
[patent_app_date] => 2017-08-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33453
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15674376
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/674376 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | Aug 9, 2017 | Abandoned |
Array
(
[id] => 14962923
[patent_doc_number] => 20190308939
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-10
[patent_title] => SALTS OF 2,6-DIMETHYLPYRIMIDONE DERIVATIVES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/316055
[patent_app_country] => US
[patent_app_date] => 2017-07-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10204
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16316055
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/316055 | Salts of 2,6-dimethylpyrimidone derivatives and uses thereof | Jul 18, 2017 | Issued |
Array
(
[id] => 14833227
[patent_doc_number] => 20190275014
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-12
[patent_title] => INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING CELL DEATH
[patent_app_type] => utility
[patent_app_number] => 16/319159
[patent_app_country] => US
[patent_app_date] => 2017-07-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35733
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16319159
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/319159 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING CELL DEATH | Jul 17, 2017 | Abandoned |
Array
(
[id] => 14929765
[patent_doc_number] => 20190300520
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-03
[patent_title] => BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 16/317218
[patent_app_country] => US
[patent_app_date] => 2017-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40614
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 417
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16317218
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/317218 | Bicyclic heteroaryl substituted compounds | Jul 12, 2017 | Issued |
Array
(
[id] => 14896821
[patent_doc_number] => 20190292176
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-26
[patent_title] => BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 16/317248
[patent_app_country] => US
[patent_app_date] => 2017-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 249342
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 679
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16317248
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/317248 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | Jul 12, 2017 | Abandoned |
Array
(
[id] => 17756241
[patent_doc_number] => 11396525
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-07-26
[patent_title] => C17, C20, and C21 substituted neuroactive steroids and their methods of use
[patent_app_type] => utility
[patent_app_number] => 16/316853
[patent_app_country] => US
[patent_app_date] => 2017-07-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 64282
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16316853
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/316853 | C17, C20, and C21 substituted neuroactive steroids and their methods of use | Jul 10, 2017 | Issued |
Array
(
[id] => 17095310
[patent_doc_number] => 20210283101
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-16
[patent_title] => METHODS AND MATERIALS FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 16/316182
[patent_app_country] => US
[patent_app_date] => 2017-07-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4322
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16316182
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/316182 | Methods and materials for treating cancer | Jul 6, 2017 | Issued |
Array
(
[id] => 13702455
[patent_doc_number] => 20170362182
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-12-21
[patent_title] => MULTIPLE-COMPONENT SOLID PHASES CONTAINING AT LEAST ONE ACTIVE PHARMACEUTICAL INGREDIENT
[patent_app_type] => utility
[patent_app_number] => 15/639223
[patent_app_country] => US
[patent_app_date] => 2017-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10208
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15639223
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/639223 | MULTIPLE-COMPONENT SOLID PHASES CONTAINING AT LEAST ONE ACTIVE PHARMACEUTICAL INGREDIENT | Jun 29, 2017 | Abandoned |
Array
(
[id] => 16343472
[patent_doc_number] => 20200308122
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => NOVEL NON-SYSTEMIC TGR5 AGONISTS
[patent_app_type] => utility
[patent_app_number] => 16/311723
[patent_app_country] => US
[patent_app_date] => 2017-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44450
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16311723
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/311723 | Non-systemic TGR5 agonists | Jun 28, 2017 | Issued |
Array
(
[id] => 14960597
[patent_doc_number] => 20190307776
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-10
[patent_title] => AZA-SUBSTITUTED INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
[patent_app_type] => utility
[patent_app_number] => 16/308016
[patent_app_country] => US
[patent_app_date] => 2017-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23514
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16308016
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/308016 | AZA-SUBSTITUTED INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Jun 27, 2017 | Abandoned |
Array
(
[id] => 15574033
[patent_doc_number] => 10577383
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-03-03
[patent_title] => Macrocyclic inhibitors of myeloperoxidase
[patent_app_type] => utility
[patent_app_number] => 16/099010
[patent_app_country] => US
[patent_app_date] => 2017-06-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28575
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16099010
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/099010 | Macrocyclic inhibitors of myeloperoxidase | Jun 25, 2017 | Issued |
Array
(
[id] => 13702505
[patent_doc_number] => 20170362207
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-12-21
[patent_title] => PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC
[patent_app_type] => utility
[patent_app_number] => 15/628968
[patent_app_country] => US
[patent_app_date] => 2017-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19950
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15628968
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/628968 | Purified cenicriviroc and purified intermediates for making cenicriviroc | Jun 20, 2017 | Issued |
Array
(
[id] => 16341594
[patent_doc_number] => 20200306244
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => WNT INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS
[patent_app_type] => utility
[patent_app_number] => 16/311366
[patent_app_country] => US
[patent_app_date] => 2017-06-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8033
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16311366
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/311366 | WNT INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | Jun 19, 2017 | Abandoned |
Array
(
[id] => 15086297
[patent_doc_number] => 20190337959
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-07
[patent_title] => Novel 4-(Aryl)-N-(3-Alkoxyfuro[2,3-b]pyrazin-2-yl)-Piperazine-1-Carboxamide Derivative and Antiproliferative Effect Thereof
[patent_app_type] => utility
[patent_app_number] => 16/308028
[patent_app_country] => US
[patent_app_date] => 2017-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11979
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16308028
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/308028 | 4-(aryl)-N-(3-alkoxyfuro[2,3-b]pyrazin-2-yl)-piperazine-1-carboxamide derivative and antiproliferative effect thereof | Jun 8, 2017 | Issued |
Array
(
[id] => 16605902
[patent_doc_number] => 10906894
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-02-02
[patent_title] => Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of g protein-coupled receptor 119
[patent_app_type] => utility
[patent_app_number] => 16/307914
[patent_app_country] => US
[patent_app_date] => 2017-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 61374
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 8
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16307914
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/307914 | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of g protein-coupled receptor 119 | Jun 7, 2017 | Issued |
Array
(
[id] => 16259931
[patent_doc_number] => 10751340
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-08-25
[patent_title] => Combination therapy to improve brain function or promote neurogenesis for treating neurodegenerative conditions
[patent_app_type] => utility
[patent_app_number] => 16/307781
[patent_app_country] => US
[patent_app_date] => 2017-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 5198
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16307781
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/307781 | Combination therapy to improve brain function or promote neurogenesis for treating neurodegenerative conditions | Jun 5, 2017 | Issued |
Array
(
[id] => 16360923
[patent_doc_number] => 20200317674
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-08
[patent_title] => PYRAZOLOPYRIMIDINE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME
[patent_app_type] => utility
[patent_app_number] => 16/305235
[patent_app_country] => US
[patent_app_date] => 2017-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30633
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -70
[patent_words_short_claim] => 138
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16305235
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/305235 | PYRAZOLOPYRIMIDINE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | Jun 4, 2017 | Abandoned |
Array
(
[id] => 14993523
[patent_doc_number] => 20190315719
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-17
[patent_title] => 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS
[patent_app_type] => utility
[patent_app_number] => 16/308349
[patent_app_country] => US
[patent_app_date] => 2017-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38772
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16308349
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/308349 | 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis | May 31, 2017 | Issued |
Array
(
[id] => 13063251
[patent_doc_number] => 10052395
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2018-08-21
[patent_title] => [
[patent_app_type] => utility
[patent_app_number] => 15/731330
[patent_app_country] => US
[patent_app_date] => 2017-05-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3635
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15731330
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/731330 | [ | May 29, 2017 | Issued |